CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (MACS1428)

This study is currently recruiting participants.
Verified January 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01227577
First received: October 21, 2010
Last updated: January 31, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2014
  Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)